DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety,
and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed
and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of
therapy.